Turkish Journal of Biology
Volume 40

Number 1

Article 22

1-1-2016

Identification of small molecule binding pocket for inhibition of
Crimean?Congo hemorrhagic fever virus OTU protease
FATİH KOCABAŞ
ENES KEMAL ERGİN

Follow this and additional works at: https://journals.tubitak.gov.tr/biology
Part of the Biology Commons

Recommended Citation
KOCABAŞ, FATİH and ERGİN, ENES KEMAL (2016) "Identification of small molecule binding pocket for
inhibition of Crimean?Congo hemorrhagic fever virus OTU protease," Turkish Journal of Biology: Vol. 40:
No. 1, Article 22. https://doi.org/10.3906/biy-1501-56
Available at: https://journals.tubitak.gov.tr/biology/vol40/iss1/22

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Biology by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Biology

Turk J Biol
(2016) 40: 239-249
© TÜBİTAK
doi:10.3906/biy-1501-56

http://journals.tubitak.gov.tr/biology/

Research Article

Identification of small molecule binding pocket for inhibition of Crimean–Congo
hemorrhagic fever virus OTU protease
1,*

2

Fatih KOCABAŞ , Enes Kemal ERGİN
Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkey
2
Department of Computer Science, North American University, Houston, TX, USA

1

Received: 16.01.2015

Accepted/Published Online: 29.07.2015

Final Version: 05.01.2016

Abstract: Crimean–Congo hemorrhagic fever virus (CCHFV) is a deadly tick-borne virus with high mortality rates. Current antivirals
lack specificity, making them susceptible to off-target effects and cytotoxicity. There is an utmost need for the identification of active
compounds for anti-CCHFV therapies. Inhibition of CCHFV ovarian tumor (OTU) protease by small molecules is an exciting potential
antiviral therapy. In this study, computational approaches based on residue homology, the binding coordinates of ligands, and correlation
analysis with in vitro data identified the pocket of Y89–W99 as the inhibition site of CCHFV OTU protease. In silico screening of more
than 600,000 compounds against this newly discovered pocket can identify potent inhibitors of CCHFV OTU protease. This novel set
of compounds exhibits a common substructure and higher binding affinities. These findings distinguish the pocket of Y89–W99 as a
pharmaceutical target for the optimization and identification of CCHFV OTU protease inhibitors that could serve as lead structures for
discovering therapies against CCHFV.
Key words: Viral OTU protease, docking, in silico screening, virtual screening, CCHFV, CCHF

1. Introduction
Crimean–Congo hemorrhagic fever virus (CCHFV)
is a deadly tick-borne virus belonging to the family
Bunyaviridae, genus Nairovirus. It constitutes a public
health threat due to its high mortality rate, up to 6% in
hospitalized patients and up to 30%–50% in severe forms
(Whitehouse, 2004; Ozkaya et al., 2010; Ergunay et al.,
2011; Bente et al., 2013). Since its first report in Crimea in
1944, there have been outbreaks in Africa, Asia, and Eastern
Europe (Gargili et al., 2011; Ergonul, 2012; Dokuzoguz
et al., 2013). Because infected ticks have been shown to
travel through migratory birds to different parts of the
world, this raises a concern regarding general healthcare
in various parts of the world (Gale et al., 2012; Lindeborg
et al., 2012; Palomar et al., 2013). There is currently no
therapeutic treatment or commercial vaccine available
for CCHFV. Due to its short incubation time (average
3–5 days), high viremia that lasts around 10 days, and
associated severe hemorrhages, it can lead to shock and
death in 1–2 weeks. This high viral activity is partly due to
an invasion mechanism that shuts down antiviral response
pathways through a unique CCHFV ovarian tumor
(OTU) protease, which has broad deconjugation activities
including deubiquitination (Arguello and Hiscott, 2007;
Frias-Staheli et al., 2007; Weber and Mirazimi, 2008).
* Correspondence: fatih.kocabas@yeditepe.edu.tr

The CCHFV OTU domain is expressed from the L
segment of the CCHFV. CCHFV OTU protease takes an
important role in viral invasion through antagonizing NF–
kB signaling (Frias-Staheli et al., 2007; van Kasteren et al.,
2012). The inhibition of antiviral activity by CCHFV OTU
occurs by the removal of ubiquitin (UB) and interferonstimulated gene products 15 (ISG15), modifications
occurring in a broad manner in the infected cells in
contrast to target-specific OTU containing mammalian
proteases (Frias-Staheli et al., 2007; Malakhova and Zhang,
2008; Akutsu et al., 2011; Capodagli et al., 2011, 2013). UB
and ISG15 share a conserved C terminus motif ‘LRLRGG’
that is recognized by CCHFV OTU protease (Akutsu et al.,
2011; Capodagli et al., 2011).
The crystal structures of the CCHFV OTU protease
bound with human UB and with ISG15 have been resolved
and deposited in the protein data bank (3PRP and 3PHX,
respectively) (Capodagli et al., 2011; James et al., 2011). A
key similarity between the two structures is the binding
of UB and ISG15 towards a similar pocket of amino
acid residues. Mutation studies in several amino acids in
close proximity to this pocket suggest that it could be a
pharmaceutical target for CCHFV OTU inhibitors (FriasStaheli et al., 2007). There are currently no CCHFV OTU
inhibitors available for use. The PubChem database reports
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a couple of preliminary studies with compounds having
a potentially inhibitory effect on OTU protease. Previous
studies on the alignment of a limited number of related
and unrelated protein datasets suggested the conservation
of amino acids D37, G38, N39, C40, W71, and H151, with
the prediction of C40 and H151 as catalytic residues in
putative OTU protease (Snijder et al., 1994, 1995; Makarova
et al., 2000; Nanao et al., 2004; Frias-Staheli et al., 2007).
However, a robust approach to determine the conserved
residues that are important for the inhibition of CCHFV
OTU protease and to utilize in silico screening to identify
CCHFV OTU inhibitors and correlate their affinities with
these proposed conserved residues was needed.
Computational chemistry for in silico screening is
now an established platform for identification of lead
compounds in the drug discovery process (Yang et al.,
2007; Sudha et al., 2008; Chang et al., 2010; Wassman et
al., 2013). This approach utilizes the prediction of binding
poses and affinities of each docked compound to the crystal
structure of a target protein. This requires knowledge of
highly conserved residues of the protein of interest. In
this study, we used computational approaches based on
residue homology, the binding coordinates of ligands,
and correlation analysis with in vitro data to determine
the conserved residues of CCHFV OTU protease. We
identified a previously unknown pocket of conserved
residues of CCHFV OTU, which provides a tool for lead
compound optimization and discovery. We performed an
in silico screening with compounds up to CID_1000000
from the PubChem database (Han et al., 2008; Wang et al.,
2011) on the newly revealed pocket of conserved residues
using the advanced docking tool AutoDock Vina (Trott
and Olson, 2009). We identified a set of compounds with
75% similar substructures. In addition, we identified fortynine CCHFV OTU-related proteins that share a similar
pocket of conserved amino acids that could be the target of
future drug discovery to combat viral and nonviral OTU
proteases and corresponding pathogens.
2. Materials and methods
2.1. CCHFV OTU protein alignments
An amino acid sequence of the CCHFV OTU was blasted
to determine the OTU-related proteins in nonredundant
protein sequences (nr) (all nonredundant GenBank CDS
translations + PDB + SwissProt + PIR + PRF) using a
blastp (protein–protein BLAST) algorithm (NCBI). A
FASTA sequence of the related protein hits was collected
to perform an amino acid alignment and to determine the
conserved amino acid residues in CCHFV OTU protease.
Multiple alignments of CCHFV OTU related protein
amino acid sequences were performed using a constraintbased multiple alignment tool (COBALT) (NCBI). The
accession numbers of the CCHFV OTU protease-related
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protein sequences are provided in Figure S1 (see links at
the end of the manuscript).
2.2. Conserved binding pocket analysis of CCHFV OTU
protease by molecular docking
The 3D coordinates of the crystal structure of OTU at a
resolution of 1.7 Å in complex with UB (PDB code: 3PRP)
were selected as the receptor model. Using AutoDockTools
(Trott and Olson, 2009), pockets of D37, C40, and
H151 residues and a pocket of Y89–W99 residues were
highlighted to determine the grid box locations with a 22–
20–20 Å search space. The 3D SDF files of the CCHFV OTU
inhibitors identified in vitro and reported in a primary
screen were downloaded from PubChem (Bioassay AID:
686976 and partially AID: 651958). Docking studies were
performed using AutoDock Vina 1.1.2 (Trott and Olson,
2009) and automated using PaDEL-ADV (Sanner et al.,
1996; Sanner, 1999). In addition, a conserved binding
pocket correlation analysis was repeated using the in
silico-identified set of compounds as described.
2.3. In silico screening
The 3D SDF files for all of the small molecules in this paper
were downloaded from PubChem (Wang et al., 2011).
The OTU protein was prepared using AutoDockTools
for docking studies, which is a module of the MGLTools.
The OTU protein (PDB code: 3PRP) was downloaded
from pdb.org in PDB format (text). Human UB and
water molecules were removed from the 3PRP and then
converted to PDBQT format using AutoDockTools.
Only compounds with 3D SDF structures provided
by PubChem were used for in silico screening. Small
molecules (ligands) up to CID_1000000 were downloaded
from PubChem (in 3D SDF format) and were ready for
docking studies. The docking studies were performed
using AutoDock Vina 1.1.2 with a 22–20–20 Å search
space centered on the pocket of Y89–W99 residues. In
silico screening was automated using PaDEL-ADV with
16 CPUs. The maximum predicted binding affinity (lowest
binding energy of –9.2 kcal/mol) of the putative inhibitors
identified in vitro was used as the cut-off value. The lower
the binding affinity, the stronger the ligand binds to the
protein. The compounds with a binding energy of at least
–9.2 kcal/mol were rescreened for the whole OTU surface
with a 50–50–50 Å search space, and a pocket of the D37,
C40, and H151 residues with a 22–20–20 Å search space.
Compounds with a binding energy of at least –9.2 kcal/
mol for both the whole OTU surface and the pocket of
Y89–W99 were determined. OTU–ligand diagrams were
prepared using AutoDockTools (MGL Tools, Scripps
Research Institute).
2.4. Cluster analysis
The top compounds were clustered according to structural
similarity (2D and 3D). Compounds with PubChem IDs
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were submitted to the Chemical Structure Clustering Tool
(PubChem, NCBI) and compounds with scores of >0.7
similarities were grouped into clusters.
2.5. Statistical analysis
Conserved binding pocket correlation analyses were
performed using Student’s t test, Pearson’s R, and the
Spearman correlation. All statistical calculations were
done in Microsoft Excel and confirmed in MATLAB
equipped with a statistics toolbox. Statistical calculations
are provided in Supplementary Tables 1, 2, and 3. Values
with P < 0.05 were considered statistically significant.
3. Results
3.1. Multiple alignment of CCHFV OTU-related proteins
identifies highly conserved residues of OTU protease
In the last decade, the pool of nucleotide sequences available
from the NCBI has rapidly increased, which has made it
possible to determine the conserved residues of CCHFV
OTU protease in related viral and nonviral proteins with
better resolution. In this study, we performed a basic
protein blast of a CCHFV OTU amino acid sequence
using an NCBI blastp algorithm and found that there are
fifty CCHFV OTU-related proteins. Doing a multiple
alignment of these fifty OTU related viral and nonviral
proteins using a COBALT algorithm, we determined the
previously undiscovered conserved residues Y89 and W99
with 100% identity and G100 with 96% identity in addition
to the previously reported D37, C40, and H151 amino acid
residues determined with at least 98% identity (Figures
1 and S1). However, we did not see any conservation of
the previously suggested G38, N38, or F152 residues in
the fifty CCHFV OTU-related viral and nonviral protein
alignments (Snijder et al., 1994, 1995; Makarova et al.,
2000; Nanao et al., 2004; Frias-Staheli et al., 2007).
Furthermore, we performed multiple alignments of
the CCHFV OTU-related viral proteins. A blast analysis at
NCBI brought only six different viral OTU-related proteins
(see Figure S2a for the phylogenic tree of OTU-related viral
proteins in related viruses). This alignment clearly showed
that there are three highly conserved areas. The highest
conservation is in the D96–L108 residues, including the
newly discovered conserved W99 and G100 residues
(Figure S2b). In addition, this newly revealed pocket
of Y89–W99 is located in the interaction site of UB and
ISG15 with CCHFV OTU protease (Figures S3a and S3b).
These findings suggest that a putative inhibition pocket of
CCHFV OTU protease could be located in the pocket of
the Y89, W99, and G100 residues or in the pocket of the
previously suggested D37–C40 residues, or the pocket of
the H151–L155 residues. Intriguingly, C40 was located in
close proximity to the Y89–W99 pocket. Moreover, when
we located these residues in the crystal structure of the

CCHFV OTU protease, we found that all of these three
conserved areas were located in close proximity to each
other; D37, C40, and H151 are facing towards the outer
surface of the OTU protease, which could be considered a
single pocket of D37, C40, and H151 residues (Figure 2).
3.2. Active compounds show selective affinity towards
the proposed inhibition pocket
Molecular docking has been used to test which pocket
of conserved residues are part of the putative protease
inhibition pocket. To this end, we got the 3D protein
structure of CCHFV OTU protease at a resolution of
1.7 Å from the Protein Database (pdb.org, 3PRP). Using
AutoDockTools, we located the pocket of D37, C40, and
H151 residues and the pocket of Y89 and W99 residues
and determined the grid box locations with a 22–20–20
Å search space (Figure 2). In addition, we outlined a grid
box with a 50–50–50 Å search space that allowed us to
scan the whole OTU surface for the affinity and binding
locations of the previously reported putative inhibitors
of OTU protease from the PubChem Database. Thus, we
collected the 3D SDF files of the CCHFV OTU inhibitors
identified in vitro, reported in a preliminary screen from
PubChem (Bioassay AID: 686976 and partially AID:
651958). Then we determined the predicted binding
affinities toward ‘whole surface’, ‘pocket of D37, C40, and
H151’, and ‘pocket of Y89, W99, G100, and S101 residues’
using the fast, and exhaustive docking software AutoDock
Vina. The analysis of 346 compounds was automated using
PaDEL-ADV. Using the coordinates and configurations
provided in Figure 2, we performed affinity calculations.
We report that the affinities toward the pocket of Y89,
W99, G100, and S101 were very similar to the OTU
surface maximum affinity calculations (P = 0.13) (Figure
3a). On the other hand, the affinities toward the pocket
of D37, C40, and H151 were significantly different than
the OTU surface maximum affinity calculations (P = 3.7 ×
10–85) (Figure 3a). In addition, affinities toward the pocket
of Y89, W99, G100, and S101 showed a high degree of
correlation with the OTU surface maximum affinities as
measured by Pearson’s R (R = 0.93) (Figure 3a). Moreover,
the binding pocket correlation analysis with the in vitro
reported compounds showed that those compounds show
higher affinities towards the proposed inhibition pocket
(pocket of Y89, W99, G100, and S101) instead of the
previously suggested catalytic residues, namely D37, C40,
and H151. For instance, CID_15944915, CID_300375, and
CID_17749659 demonstrate the same or highly similar
affinities toward the pocket of Y89–S101 and the whole
surface maximum affinity. This is also evident when we
looked at where these compounds are predicted to bind
in the whole OTU surface affinity analysis (Figure 3b, left
column). Their predicted maximum affinity is toward the
pocket of Y89, W99, G100, and S101.
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Figure 1. Multiple alignment of the CCHFV OTU protease-related proteins. A basic local alignment search of the OTU protein sequence at NCBI Blast resulted in fifty different
proteins (see Figure S1 for descriptions of each of the proteins) in a nonredundant protein database. Multiple alignments of those proteins by NCBI COBALT demonstrated
conserved amino acid residues at D37, C40, Y89, W99, G100, and H151 within at least 96% of aligned proteins. Note that D37, Y89, and W99 were 100% conserved across 50 OTU
related proteins, indicating their high degree of functional importance.
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Figure 2. Analysis of the CCHFV OTU protease inhibition pocket by molecular docking. Top row = OTU ribbon diagram, where the
proposed residues as catalytic residues are highlighted. Middle row = OTU surface with the positions of the conserved residues marked.
Bottom rows = grid box showing where molecular docking took place in a cube, with its coordinates and configuration.

3.3. In silico screening toward the pocket of Y89, W99,
G100, and S101
The precise discovery of an inhibition pocket of CCHFV
OTU protease using ensemble-based docking allowed
us to design an in silico screen for inhibitors of CCHFV
OTU with higher affinities. In vitro screening is often
costly and the failure rate is still high. Although there
are hits that show promise, they have either high IC50
values or cytotoxicity. The utilization of bioinformatic
tools that foresee and provide lead compounds with
predicted higher affinities could yield lower IC50 and
thus lower toxicity. Therefore, we performed an in
silico screening toward the newly revealed pocket of
Y89, W99, G100, and S101. The screening included
compounds with 3D structures available at PubChem

up to CID_1000000. Docking studies were performed
using AutoDock Vina and PaDEL-ADV with a 22–
20–20 Å search space centered on the pocket of Y89
and W99 residues. We identified 313 compounds with
higher affinities (lower binding energy) than previously
reported (CID_15944915, binding affinity = –9.2 kcal/
mol) (Supplementary Tables 3 and 4).
3.4. In silico screening identifies a novel set of compounds
with higher affinity toward the pocket of Y89, W99,
G100, and S101
A binding pocket correlation analysis was repeated using
a set of compounds identified in silico with an affinity
of at least –9.2 kcal/mol. We performed docking for the
whole OTU surface with a 50–50–50 Å search space, and
a pocket of D37, C40, and H151 residues with a 22–20–
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Figure 3. Binding pocket correlation analysis with compounds identified in vitro. A) Table of compounds showing affinity estimates towards
the whole OTU surface, the previously suggested catalytic residues (D37, C40, and H151), and the proposed binding pocket (Y89, W99,
G100, and S101). Note that the Y89, W99, G100, and S101 site affinities of the compounds are significantly similar to the whole surface
maximum affinities and show a high degree of correlation (R = 0.93). However, affinity towards the catalytic residue (D37, C40, and H151)
is significantly different (P < 0.001) and is lower (average difference = – 2.2) compared to the whole surface maximum affinity scores. B)
Representative images of the compounds identified in vitro docked into the whole OTU or the pockets of D37–H151 and Y89–W99 show
that the putative inhibitors identified in vitro reported in PubChem against CCHFV OTU protease show a preference to bind to the pocket
of Y89–W99, both in whole surface molecular docking and Y89–W99–G100–S100 molecular docking. See Supplementary Table 1 (see links
at the end of the manuscript) for larger datasets and Supplementary Table 2 for Swissdock verification.

20 Å search space. We show that compounds with an
affinity of at least –9.2 kcal/mol on the whole OTU surface
docking were not significantly different than the affinities
towards the proposed binding pocket of Y89, W99, G100,
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and S101 (P = 0.30) (Figure 4a; Supplementary Tables 3
and 4). Similar to the binding pocket correlation analysis
with compounds identified in vitro towards the pocket of
D37, C40 and H151, compounds identified in silico show
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Figure 4. Binding pocket correlation analysis with compounds identified in silico. A) The set of compounds identified in silico from a
virtual screen of compounds up to CID_1000000 that demonstrate preferential binding to the pocket of Y89–W99–G100–S101 residues
instead of the previously proposed catalytic domains (D37, C40, and H151). See Supplementary Table 3 for larger datasets. B) Representative
images of compounds identified in silico docked into the whole OTU surface, the D37–H151 pocket, and the Y89–W99 pocket. See
Supplementary Table 4 for the binding affinity predictions of the compounds up to CID_1000000 tested for the Y89–W99 pocket.

significantly different affinities compared to the whole
surface maximum affinities (P = 1.5 × 10–240). In addition,
hits identified in silico demonstrated a correlated affinity
between the whole surface maximum affinities and the

proposed binding pocket affinities (R = 0.80), while there
were no correlations between the whole OTU surface
maximum affinities and the previously suggested catalytic
site affinities (R = 0.46). Moreover, hits identified in silico
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demonstrated a preferential binding to the pocket of Y89,
W99, G100, and S101 on the whole OTU surface docking
(Figure 4b). For instance, CID_62448, CID_377321, and
CID_74783 demonstrated the same affinity predictions
and were found to bind to the same location (the pocket
of Y89–S101), as determined by both the whole surface
and the proposed pocket of Y89–S101 molecular docking.
This is in contrast to the D37, C40, and H151 pocket,
where affinities are largely different than the whole surface
maximum affinities of the compounds CID_62448,
CID_377321, and CID_74783.

3.5. Structural clustering of in silico hits identifies
common substructures
We performed a structural classification of hits identified
in silico using 2D and 3D Tanimoto similarity (Figures
5a and S4a and S4b). We found that there are common
substructures shared in 75% of the compounds described
in the set (Figures 4a, 5a, and 5b). Unique compounds with
unique structures were put into group 1 while others with
at least 0.7 similarity scores were put into group 2 (Figure
5c). The investigation of the group 2 compounds having at
least a –10.8 kcal/mol predicted affinity towards CCHFV

Figure 5. Clustering of hits identified in silico pinpoints common substructures. A) Structure clustering of in silico hits based on 2D
Tanimoto similarity. Note that the majority have a similarity score greater than 0.7. (See Figure S4 for 3D structure similarities). B)
Substructure analysis identifies common substructures among 75% of the set as shown in blue on CID 77186. C) Group 1 is composed of
nonclustered compounds CID 113522, CID 77186, and CID 62448 with unique molecular structures. Group 2 is composed of compounds
with high structure similarity scores up to 0.9. Note that all of the compounds listed here have predicted affinity scores of at least –10.8.
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OTU protease provided a novel group of compounds for
generation of CCHFV antivirals.
3.6. Cytotoxicity analysis of putative inhibitors of
CCHFV OTU protease
It is possible that the identified hits could have cytotoxicity.
Thus, we analyzed the hits identified in silico in the
PubChem bioassays database to determine if they have
any reported cytotoxicity (Han et al., 2008). None of the
hits in Figure 4a were reported to have any cytotoxicity. In
addition, compounds CID_377321 and CID_388441 were
tested on various cell lines and showed no cytotoxicity
as reported by PubChem bioassays. On the other hand,
70% of putative OTU protease inhibitors identified in
vitro showed in Figure 3a are predicted to be potentially
cytotoxic as reported in PubChem (see Supplementary
Table 1 for more info). We have determined some
potentially cytotoxic and noncytotoxic CCHFV OTU
protease inhibitors that could be used in further evaluation
of treatments of CCHFV infections.
4. Discussion
It is a great challenge to identify compounds that can
inhibit the virulence of deadly viruses. Large library
screenings are costly and require additional validation
and toxicity analysis. On the other hand, virtual screening
could provide the means to filter out compounds with low
affinity, thus possibly providing compounds with high IC50
values that could overcome the toxicities related to high
doses. Computational identification of such compounds
requires accurate knowledge of the conserved residues in
the inhibition pocket of the target protein. In this study,
we used a computational method based on the correlation
analysis of putative inhibitors with the predicted pockets of
highly conserved residues to identify the inhibition pocket
of the CCHFV OTU protease. Robust homology studies
among CCHFV OTU protease-related proteins revealed
a new pocket of conserved residues in close proximity
to the UB and ISG15 binding sites. We have shown that
the putative OTU protease inhibitors identified in vitro
preferentially bind to the newly revealed pocket of Y89–
W99 rather than the previously suggested D37, C40, and
H151 residues.
Mutation studies in viral OTU protease are in alignment
with our findings. Mutation studies with a closely related
OTU protease at H151 resulted in the destabilization
of OTU in a human cell line (HEK293 cells) but not in
a monkey cell line (Vero cells) (Bakshi et al., 2013). This
points to a major difference between human and other
vertebrates in the invasion of CCHFV and related viruses
and the requirement of H151 in the stability of OTU
protein in human tissues, rather than involving OTU
protease activity. Moreover, it has been recently shown
that a mutated OTU protein at C40 still has a significant

effect on the induction of the JAK/STAT and TNF-α /NF-k
B pathways, although it loses cleavage ability (Bergeron et
al., 2010; Bakshi et al., 2013). This suggests that C40, which
is partially located in the pocket of Y89–W99, is required
for CCHFV OTU protease activity.
We have identified the Y89–W99 pocket of CCHFV
OTU protease as a pharmaceutical target for optimization
and identification of CCHFV OTU protease inhibitors.
The discovery of the Y89–W99 pocket allowed us to design
in silico screening to identify compounds with higher
affinities toward the OTU protease inhibition pocket. We
automated the in silico screening system using PaDELADV and successfully identified compounds that show
preferential binding to the Y89–W99 pocket with higher
binding affinities (lower binding energies). Our screening
provided a cost-effective and timesaving screening process
for identification of the inhibition pocket of CCHFV
OTU protease and highly potent inhibitors. This led us
to identify over 300 candidate compounds. Among these
compounds, we found that NSC658721 (CID_377321)
and NSC683337 (CID_388441) have at least a –11.0 kcal/
mol calculated binding affinity towards the pocket of
Y89–W89 and the whole OTU protease. In addition, we
found a common backbone of the chemical structure that
could shed light on future inhibitor development studies
targeting the pocket of viral OTU protease. Further
investigation of these compounds is required to determine
whether they could be used for the inactivation of invasion
mechanisms through the inhibition of viral OTU protease
activity in the fight against CCHFV infections.
In addition, robust characterization of CCHFV OTUrelated proteins led us to discover that CCHFV OTU
is related to intracellular parasites that use OTU-like
proteases. They are likely to use a similar system to invade
cells and overcome innate cellular immunity through the
broad deconjugation activities of OTU protease. This study
also highlights that lead compounds identified in vitro
could be used successfully to determine the inhibition
pocket of proteins through a correlation analysis following
a computational calculation of docking affinities of
compounds with the target protein. This study could
be extended experimentally to evaluate the biological
activity of the identified compounds, which would help
in designing compounds with higher potency and lower
toxicity.
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